Denali deal and F-star’s innovative asset centric business model

November 24, 2016 Christoph Graener

 

Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star’s asset-centric business strategy, the company’s recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Jane Dancer – Chief Business Officer, F-star

 

Previous Article
How are regulatory changes affecting early stage R&D in China?
How are regulatory changes affecting early stage R&D in China?

Darren Ji discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes f...

Next Article
Freshly-appointed Auspherix CEO highlights new antibiotic class
Freshly-appointed Auspherix CEO highlights new antibiotic class

Auspherix’s newly-appointed CEO talks about the science behind the company’s gram-negative targeting new an...